AZ's Covid drug wins review

Posted 21 January 2022 AM

AstraZeneca's Covid therapeutic Evusheld was the only new medicine accepted for review by the TGA last month while most other applications accepted were from companies seeking to expand their cancer drugs.

Evusheld is a combination of two long-acting monoclonal antibodies (tixagevimab and cilgavimab), administered as two separate consecutive intramuscular injections. While the proposed indication states 'for treatment of COVID', the company was granted a provisional determination on 4 November for the prevention of Covid in patients aged 12 years and older.

To see the whole article, please login